News

Microbix Presenting at Florida Capital Event Conference

Meetings with Growth-Oriented Investors, November 17 to 19, 2023MISSISSAUGA, Ontario, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX:…

1 year ago

Emergex Signs Contract of £1.79M with the UK Department of Health and Social Care’s UK Vaccine Network (“UKVN”) to Advance Its Novel Synthetic T Cell-Priming Set-Point Candidate Against Chikungunya Virus

ABINGDON, United Kingdom, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major…

1 year ago

Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology

Single treatment of bizaxofusp doubled mOS (14.5 months vs. 7.2 months) irrespective of IL4R expression (high or low) compared to…

1 year ago

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual MeetingBRISBANE, Calif., Nov.…

1 year ago

Mendus Announces Nomination Committee for the 2024 Annual General Meeting

Press Release Stockholm, Sweden, November 17, 2023 Mendus AB (publ: IMMU.ST) announced today that the members of the Nomination Committee…

1 year ago

First Product Incorporating Arecor’s Arestat Technology, At220, Launched in Europe

Arecor Therapeutics plc(“Arecor” or the “Group”) FIRST PRODUCT INCORPORATING ARECOR’S ARESTAT TECHNOLOGY, AT220, LAUNCHED IN EUROPE First commercial sale triggers…

1 year ago

Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award

LONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”),…

1 year ago

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023 aXess demonstrated exceptional patency rates…

1 year ago

Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma

TAIPEI, Taiwan and SAN DIGEO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the…

1 year ago

Precipio Announces Q3-2023 Shareholder Update Call

Conference Call to be held on November 20th, 2023 at 5:00 PM ESTNEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE)…

1 year ago